2023 annual financial data
Relmada Therapeutics 2023 Net income growth
Direct answer
Net income growth was 37.09%.
Operating income was -103,702,000 USD and net income was -98,792,000 USD.
Operating cash flow was -51,659,206 USD.
Get free Relmada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -103,702,000 USD
- Net income
- -98,792,000 USD
- Operating cash flow
- -51,659,206 USD